texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Brain Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Breast Cancer

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Cervical Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Colon Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Esophageal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Essential Thrombocythemia

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Fallopian Tube Cancer

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Gastric Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Head and Neck Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Hematologic

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Bedford

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Grapevine

Phase: IV

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Liver Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Lung Cancer

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Lymphomas

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Mesothelioma

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Myelofibrosis

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Neuroendocrine Tumors

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Ovarian Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Pancreatic Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Penile Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Peritoneal Cancer

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Prostate Cancer

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Rectal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Solid Tumors

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Testicular Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Thymomas

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Thyroid Cancer

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Uterine Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Vaginal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Texas Oncology-Arlington North

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington North

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Texas Oncology-Arlington South

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Bedford

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Texas Oncology-Fort Worth Cancer Center

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Texas Oncology-Grapevine

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Grapevine

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

No Phase

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Phase I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Phase II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Phase III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph 3 pembro+ipi, 1L adv/rec NSCLC View

Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Avelumab Ovarian JAVELIN 100 PARP View

Description: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP 100)(B9991030)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Phase III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Phase IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Bedford

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Grapevine

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV